Endocannabinoids and related fatty acid derivatives in pain modulation. (abst – 2002) http://www.ncbi.nlm.nih.gov/pubmed/12505698
Characterisation of the vasorelaxant properties of the novel endocannabinoid Narachidonoyl- dopamine (NADA). (full – 2004) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574254/
TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid Narachidonoyl- dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. (abst – 2004) http://www.ncbi.nlm.nih.gov/pubmed/15245490
Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. (full – 2005) http://www.jimmunol.org/content/175/6/3990.long
Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and Narachidonoyldopamine (NADA) in the rat isolated aorta. (abst – 2005) http://www.ncbi.nlm.nih.gov/pubmed/15659311
Targeted lipidomics: fatty acid amides and pain modulation. (abst – 2005) http://www.ncbi.nlm.nih.gov/pubmed/16099389
Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. (abst – 2007) http://www.ncbi.nlm.nih.gov/pubmed/17459108
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. (full – 2008) http://molpharm.aspetjournals.org/content/73/2/441.long
N-arachidonoyl dopamine is a possible factor of the rate of tentacle formation in freshwater hydra (abst – 2008) http://www.ncbi.nlm.nih.gov/pubmed/18409382
The role of the CB1 receptor in the regulation of sleep. (abst – 2008) http://www.ncbi.nlm.nih.gov/pubmed/18514375
The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine (full – 2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757501/
Endocannabinoids in nervous system health and disease: the big picture in a nutshell (full – 2012) http://rstb.royalsocietypublishing.o...1607/3193.full
The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes (full – 2012) http://ajpgi.physiology.org/content/302/8/G873.long
The endocannabinoid system: an overview (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303140/
The endocannabinoid N-arachidonoyldopamine (NADA) exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1 (CB(1)). (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22186081
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. (full – 2014) http://www.jbc.org/content/early/201...13.536953.long
Vascular targets for cannabinoids: animal and human studies. (full – 2014) http://onlinelibrary.wiley.com/doi/1...bph.12560/full
Effect of N-Arachidonoyl Dopamine on Activity of Neuronal Network in Primary Hippocampus Culture upon Hypoxia Modelling. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24771427
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24644287
Characterisation of the vasorelaxant properties of the novel endocannabinoid Narachidonoyl- dopamine (NADA). (full – 2004) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574254/
TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid Narachidonoyl- dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. (abst – 2004) http://www.ncbi.nlm.nih.gov/pubmed/15245490
Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. (full – 2005) http://www.jimmunol.org/content/175/6/3990.long
Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and Narachidonoyldopamine (NADA) in the rat isolated aorta. (abst – 2005) http://www.ncbi.nlm.nih.gov/pubmed/15659311
Targeted lipidomics: fatty acid amides and pain modulation. (abst – 2005) http://www.ncbi.nlm.nih.gov/pubmed/16099389
Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. (abst – 2007) http://www.ncbi.nlm.nih.gov/pubmed/17459108
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. (full – 2008) http://molpharm.aspetjournals.org/content/73/2/441.long
N-arachidonoyl dopamine is a possible factor of the rate of tentacle formation in freshwater hydra (abst – 2008) http://www.ncbi.nlm.nih.gov/pubmed/18409382
The role of the CB1 receptor in the regulation of sleep. (abst – 2008) http://www.ncbi.nlm.nih.gov/pubmed/18514375
The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine (full – 2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757501/
Endocannabinoids in nervous system health and disease: the big picture in a nutshell (full – 2012) http://rstb.royalsocietypublishing.o...1607/3193.full
The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes (full – 2012) http://ajpgi.physiology.org/content/302/8/G873.long
The endocannabinoid system: an overview (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303140/
The endocannabinoid N-arachidonoyldopamine (NADA) exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1 (CB(1)). (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22186081
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. (full – 2014) http://www.jbc.org/content/early/201...13.536953.long
Vascular targets for cannabinoids: animal and human studies. (full – 2014) http://onlinelibrary.wiley.com/doi/1...bph.12560/full
Effect of N-Arachidonoyl Dopamine on Activity of Neuronal Network in Primary Hippocampus Culture upon Hypoxia Modelling. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24771427
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24644287